Objective: The main aim was to explore the changes in hand-grip strength in patients with Duchenne muscular dystrophy (DMD) aged 5-29 years. Secondary aims were to test the effect of mutation, ambulatory status and glucocorticoid use on grip strength and its changes over time and to compute the number of subjects needed for a clinical trial to stabilize grip strength.
Methods: The analysis was performed on data collected during five international natural history studies on a cohort of DMD patients. Two hundred and two patients with genetically proven DMD were pooled from five different natural history studies. Excepting 13 patients with only one visit, the mean duration of follow-up was 2.2 ± 1.6 years. A total of 977 measurement points were collected. Grip strength was measured on the dominant side with a high precision dynamometer. The analysis was performed using absolute values and normalized values expressed in percentage of predicted values for age.
Results: For absolute values, grip strength typically increased in ambulatory boys and decreased in non-ambulatory patients. However, when normalized, grip strength was already reduced at age 5 years and thereafter continued to fall away from normal values. The weaker the patients, the less strength they are prone to lose over again.
Interpretation: Grip strength constitutes a sensitive and continuous outcome measure that can be used across all stages of DMD. Its measurement is easy to standardized, can be used in ambulatory and non-ambulatory patients and does not present any floor or ceiling effect. It is thus attractive as an outcome measure in therapeutic trials.
Keywords: Duchenne muscular dystrophy; Grip strength; Outcome measures.
The association of hand grip strength with functional measures in non-ambulatory children with Duchenne muscular dystrophy.Arq Neuropsiquiatr. 2019 Nov;77(11):792-796. doi: 10.1590/0004-282X20190161. Arq Neuropsiquiatr. 2019. PMID: 31826135
Longitudinal assessment of grip strength using bulb dynamometer in Duchenne Muscular Dystrophy.Braz J Phys Ther. 2014 May-Jun;18(3):245-51. doi: 10.1590/bjpt-rbf.2014.0031. Epub 2014 Jun 24. Braz J Phys Ther. 2014. PMID: 25003277 Free PMC article. Clinical Trial.
Glucocorticoid corticosteroids for Duchenne muscular dystrophy.Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003725. doi: 10.1002/14651858.CD003725.pub3. Cochrane Database Syst Rev. 2008. PMID: 18254031 Updated. Review.
Glucocorticoid corticosteroids for Duchenne muscular dystrophy.Cochrane Database Syst Rev. 2004;(2):CD003725. doi: 10.1002/14651858.CD003725.pub2. Cochrane Database Syst Rev. 2004. PMID: 15106215 Updated. Review.
Corticosteroids for the treatment of Duchenne muscular dystrophy.Cochrane Database Syst Rev. 2016 May 5;(5):CD003725. doi: 10.1002/14651858.CD003725.pub4. Cochrane Database Syst Rev. 2016. PMID: 27149418 Review.